Alfa Cytology, a provider of biomedical research support services, has announced the enhancement of its radiopharmaceutical development portfolio by integrating custom radiolabeling with physicochemical characterization capabilities. This move aims to offer comprehensive support for biotechnology and pharmaceutical companies working on targeted radiopharmaceuticals and antibody-drug conjugates (ADCs).
The integration addresses a critical need in the field: while radiolabeling is essential for tracking and imaging, the success of a candidate depends on key attributes such as radiochemical purity, stability, lipophilicity, and target-binding capability. Alfa Cytology’s combined services allow researchers to obtain high-quality radiolabeled products and systematically evaluate these critical quality attributes, thereby reducing uncertainty and improving development efficiency.
The company’s custom radiolabeling services support antibodies, ADCs, peptide therapeutics, small molecules, and other targeted compounds, using a variety of radionuclides for diagnostic and therapeutic applications. These services are applicable to pharmacokinetic studies, biodistribution analysis, molecular imaging, and overall radiopharmaceutical development. Meanwhile, the physicochemical characterization services cover analysis of radiochemical purity, stability, lipophilicity (LogP/LogD), and immunoreactivity, generating reliable data to support subsequent research.
“The demand for high-quality radiolabeling and physicochemical characterization data continues to grow as radiopharmaceutical development advances,” said a spokesperson for Alfa Cytology. “By integrating our technical capabilities, we aim to provide customers with more efficient research support and help advance the development of innovative radiopharmaceuticals and targeted therapies.”
Radiopharmaceuticals have become an important area in precision medicine, with increasing research utilizing radiolabeling for cancer diagnosis and targeted therapy. The rapid growth of ADCs, peptide therapeutics, and targeted small molecules has further fueled demand for advanced radiopharmaceutical development capabilities. Alfa Cytology’s enhanced service portfolio is designed to meet this growing need by covering key research activities from radiolabeling to quality assessment.
For more information on Alfa Cytology’s radiopharmaceutical development services, visit their custom radiolabeling for ADCs and targeted radiopharmaceuticals services and Radiopharmaceutical Physicochemical Characterization CRO services pages.
